drugset / Trial / NCT02155582
Copanlisib Pharmacodynamic Study
RandomizedParallel-groupOpen-labelOther
Summary
This study aims to analyze what the study drug does to the body and its relationship to drug levels and safety after patients with advanced cancer have been treated with copanlisib in different dose groups.
Timeline
- Start
- 2014-08-12
- Primary completion
- 2016-10-04
- Completion
- 2017-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 0.4 mg/kg | Intravenous |
| Subject | Copanlisib | Small molecule | 0.8 mg/kg | Intravenous |
| Subject | Copanlisib | Small molecule | 45 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |